Acute Care pp 172-177 | Cite as

Prophylactic Antiplatelet Therapy in Children with Cyanotic Heart Disease

  • A. H. Sutor
  • B. Schmidt
  • H. P. Lorenz
  • J. Vogt
Conference paper
Part of the Anaesthesiology and Intensive Care Medicine/Anaesthesiologie und Intensivmedizin book series (A+I, volume 116)


Children with congenital cyanotic heart disease are prone to hemorrhagic as well as thrombo-embolic complications. Formerly it has been suggested that the alterations of the hemodynamics existing in this kind of disease caused continuous disseminated intravascular coagulation with consumption coagulopathy. More recent kinetic studies however showed that in cyanotic heart disease only the survival time of the thrombocytes is shortened while the fibrinogen consumption is normal (1, 3, 4). From the aspect of coagulation physiology we have a similar situation in the hemolytic uremic syndrome. Therefore we treat patients with hemolytic uremic syndrome not with anticoagulants but with antiplatelet drugs, in order to interrupt the vicious circle platelet induced thrombosis platelet → consumption → thrombocytic bleeding tendency (2). Best results were obtained with the combination of ASA (Aspirin) and Dipyridamol (Persantin) (1). The following is a report of our preliminary experiences with antiplatelet therapy in children with congenital cyanotic heart disease.


Antiplatelet Therapy Hemolytic Uremic Syndrome Bleeding Time Thromboembolic Complication Antiplatelet Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harker, L.A., Slichter, S.J.: Platelet and fibrinogen consumption in man. New Engl. J. Med.: 287, 999 (1972)Google Scholar
  2. 2.
    Sutor, A.H., Künzer, W.: Therapeutische Probleme bei Verbrauchskoagulopathien. Pädiatr. Prax. 16, 157 (1975/76)Google Scholar
  3. 3.
    Waldmann, J.D., Czapek, E.E., Paul, M.H., Schwertz, A.D., Levin, D.L., Schindler, J.G.: Shortened platelet survival in cyanotic heart disease. J. Pediatr. 87, 77 (1975)CrossRefGoogle Scholar
  4. 4.
    Wedemeyer, A., Edson, J.R., Keivit, W.: Coagulation in cyanotic congenital heart disease. Amer. J. Dis. Child., 124, 656 (1972)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1979

Authors and Affiliations

  • A. H. Sutor
  • B. Schmidt
  • H. P. Lorenz
  • J. Vogt

There are no affiliations available

Personalised recommendations